AGILENT TECHNOLOGIES, INC.

Alpha Score of 55 reflects moderate overall profile with moderate momentum, moderate value, moderate quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.

Agilent Technologies Inc. provides application-focused solutions for life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three key segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment delivers instruments, software, and services to identify, quantify, and analyze physical and biological properties of substances, supporting clinical and life sciences research at molecular and cellular levels. The Diagnostics and Genomics segment supplies reagents, instruments, software, consumables, and active pharmaceutical ingredients for oligo-based therapeutics, advancing genomics, pathology, and companion diagnostics. Agilent CrossLab offers startup support, operational training, compliance services, software-as-a-service, asset management, and consultative services to optimize laboratory performance. Notable products include liquid chromatography systems, mass spectrometry, and innovations like the Altura line of HPLC columns for biotherapeutic testing, xCELLigence RTCA eSight with 21 CFR Part 11 compliance software, and Insight Series for airport security screening. Founded in 1999 and headquartered in Santa Clara, California, Agilent Technologies Inc. plays a vital role in enabling scientific breakthroughs across pharmaceuticals, biotechnology, and environmental testing.